{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:58:23Z","timestamp":1791665903399,"version":"4.3.4"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Trimetazidine is an antianginal medication approved in numerous countries for use in the symptomatic treatment of stable coronary artery disease and angina pectoris. Its main mechanism of action revolves around the inhibition of \u03b2-oxidation of free fatty acids in the myocardium, in addition to its antioxidant properties and inhibition of cardiac fibrosis. Based on current evidence, trimetazidine is classified by European guidelines as a second-line antianginal agent and as an add-on for the symptomatic treatment of stable angina in patients not adequately controlled with first-line antianginal therapies such as beta-blockers. However, its role in the treatment of cardiovascular disease extends past coronary artery disease, as numerous studies have demonstrated its potential benefit in heart failure patients as well. Unfortunately, trimetazidine\u2019s role in the treatment of heart failure is still not clearly identified, since most studies on this topic were underpowered and unable to reach a decisive conclusion regarding any potential mortality benefits in heart failure. Current European guidelines have categorized trimetazidine as a class IIb recommendation in patients with heart failure with reduced ejection fraction and angina because of its additive effects of improved left ventricular function and anginal symptom relief in patients already on beta-blockers. Additionally, trimetazidine\u2019s use in coronary interventions (ie, percutaneous coronary intervention and coronary artery bypass grafting) showed a reduction in the frequency of anginal attacks and myocardial damage, but the studies were also underpowered and therefore unable to conclusively determine whether trimetazidine should be incorporated in guideline-directed therapy for coronary interventions.<\/jats:p>","DOI":"10.1097\/crd.0000000000000862","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T17:00:18Z","timestamp":1738861218000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Trimetazidine Use in Cardiovascular Disease"],"prefix":"10.1097","author":[{"given":"Mohammed","family":"Kallash","sequence":"first","affiliation":[{"name":"Department of Medicine, School of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, New York Medical College, Valhalla, NY"},{"name":"Department of Medicine, Westchester Medical Center, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"R1-20250206","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s40265-014-0233-5","article-title":"Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease.","volume":"74","author":"Chrusciel","year":"2014","journal-title":"Drugs"},{"key":"R2-20250206","doi-asserted-by":"crossref","first-page":"e871","DOI":"10.1097\/MJT.0000000000000180","article-title":"Trimetazidine in practice: review of the clinical and experimental evidence.","volume":"23","author":"D\u00e9zsi","year":"2016","journal-title":"Am J Ther"},{"key":"R4-20250206","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.RES.86.5.580","article-title":"The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.","volume":"86","author":"Kantor","year":"2000","journal-title":"Circ Res"},{"key":"R5-20250206","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1006\/jmcc.1994.1116","article-title":"Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation.","volume":"26","author":"Fantini","year":"1994","journal-title":"J Mol Cell Cardiol"},{"key":"R6-20250206","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/107424840501000402","article-title":"Metabolic modulators for chronic cardiac ischemia.","volume":"10","author":"Parang","year":"2005","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R7-20250206","first-page":"548","article-title":"Effect of trimetazidine on biological activity of neutrophils in patients with transient myocardial ischemia induced by exercise testing.","volume":"9","author":"Kowalski","year":"2000","journal-title":"Pol Merkuriusz Lek"},{"key":"R8-20250206","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0022-2828(86)80433-3","article-title":"Effects of trimetazidine on action potentials and membrane currents of guinea-pig ventricular myocytes.","volume":"18","author":"Kiyosue","year":"1986","journal-title":"J Mol Cell Cardiol"},{"key":"R9-20250206","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1253\/circj.70.1169","article-title":"Trimetazidine reduces oxidative stress in cardiac Surgery.","volume":"70","author":"Iskesen","year":"2006","journal-title":"Circ J"},{"key":"R10-20250206","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/cvr\/cvq181","article-title":"Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase-ROS-CTGF pathway.","volume":"88","author":"Liu","year":"2010","journal-title":"Cardiovasc Res"},{"key":"R11-20250206","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0008-6363(96)00112-5","article-title":"Pre-treatment with trimetazidine increases sarcolemma mechanical resistance in reoxygenated myocytes.","volume":"32","author":"Ruiz-Meana","year":"1996","journal-title":"Cardiovasc Res"},{"key":"R12-20250206","first-page":"S17","article-title":"The role of trimetazidine in inhibiting cardiomyocyte apoptosis.","volume":"3","author":"Ruixing","year":"2007","journal-title":"Arch Med Sci"},{"key":"R13-20250206","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.yjmcc.2005.09.012","article-title":"Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia\u2013reperfusion injury.","volume":"39","author":"Argaud","year":"2005","journal-title":"J Mol Cell Cardiol"},{"key":"R14-20250206","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.mehy.2010.09.012","article-title":"Early administration of trimetazidine may prevent or ameliorate diabetic cardiomyopathy.","volume":"76","author":"Wenmeng","year":"2011","journal-title":"Med Hypotheses"},{"key":"R15-20250206","first-page":"533","article-title":"Efficacy and tolerance of trimetazidine, a metabolic antianginal, in combination with a hemodynamic antianginal in stable exertion angina. TRIMPOL I, a multicenter study.","volume":"29","author":"Szwed","year":"2000","journal-title":"Presse Med"},{"key":"R16-20250206","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1053\/euhj.2001.2896","article-title":"Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand.","volume":"22","author":"Szwed","year":"2001","journal-title":"Eur Heart J"},{"key":"R17-20250206","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00129784-200303050-00007","article-title":"Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35\u2009mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study.","volume":"3","author":"Sellier","year":"2003","journal-title":"Am J Cardiovasc Drugs"},{"key":"R18-20250206","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ijcard.2012.11.001","article-title":"Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina--the VASCO-angina study.","volume":"168","author":"Vitale","year":"2013","journal-title":"Int J Cardiol"},{"key":"R19-20250206","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/hrt.78.4.353","article-title":"Combination treatment with trimetazidine and diltiazem in stable angina pectoris.","volume":"78","author":"Manchanda","year":"1997","journal-title":"Heart"},{"key":"R20-20250206","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0167-5273(02)00367-4","article-title":"Treatment of stable angina with low dose diltiazem in combination with the metabolic agent trimetazidine.","volume":"88","author":"Manchanda","year":"2003","journal-title":"Int J Cardiol"},{"key":"R21-20250206","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000332369","article-title":"Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis.","volume":"120","author":"Danchin","year":"2011","journal-title":"Cardiology"},{"key":"R22-20250206","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00019501-200304000-00010","article-title":"Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials.","volume":"14","author":"Marzilli","year":"2003","journal-title":"Coron Artery Dis"},{"key":"R23-20250206","first-page":"CD003614","article-title":"Trimetazidine for stable angina.","author":"Ciapponi","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"R24-20250206","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/oxfordjournals.eurheartj.a059685","article-title":"Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy.","volume":"11","author":"Brottier","year":"1990","journal-title":"Eur Heart J"},{"key":"R25-20250206","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0002-9149(98)00500-1","article-title":"Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease.","volume":"82","author":"Lu","year":"1998","journal-title":"Am J Cardiol"},{"key":"R26-20250206","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1016\/S0002-8703(03)00415-0","article-title":"Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.","volume":"146","author":"Fragasso","year":"2003","journal-title":"Am Heart J"},{"key":"R27-20250206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2840-2-16","article-title":"Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study.","volume":"2","author":"Rosano","year":"2003","journal-title":"Cardiovasc Diabetol"},{"key":"R28-20250206","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/00129784-200505040-00006","article-title":"Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study.","volume":"5","author":"El-Kady","year":"2005","journal-title":"Am J Cardiovasc Drugs"},{"key":"R29-20250206","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jacc.2006.03.060","article-title":"A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.","volume":"48","author":"Fragasso","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R30-20250206","doi-asserted-by":"crossref","first-page":"602.e1","DOI":"10.1016\/j.ahj.2007.06.033","article-title":"Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy.","volume":"154","author":"Di Napoli","year":"2007","journal-title":"Am Heart J"},{"key":"R31-20250206","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/hrt.2011.226332","article-title":"Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure.","volume":"97","author":"Fragasso","year":"2011","journal-title":"Heart"},{"key":"R32-20250206","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1590\/S0066-782X2009000800014","article-title":"The effects of trimetazidine on heart rate variability in patients with heart failure.","volume":"93","author":"Gunes","year":"2009","journal-title":"Arq Bras Cardiol"},{"key":"R33-20250206","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1540-8159.2008.02208.x","article-title":"The effects of trimetazidine on p-wave duration and dispersion in heart failure patients.","volume":"32","author":"Gunes","year":"2009","journal-title":"Pacing Clin Electrophysiol"},{"key":"R34-20250206","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1074248409354601","article-title":"Trimetazidine shortens QTc interval in patients with ischemic heart failure.","volume":"15","author":"Zemljic","year":"2010","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R35-20250206","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/hrt.2010.208751","article-title":"Trimetazidine: a meta-analysis of randomised controlled trials in heart failure.","volume":"97","author":"Gao","year":"2011","journal-title":"Heart"},{"key":"R36-20250206","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jacc.2011.11.027","article-title":"Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis.","volume":"59","author":"Zhang","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R37-20250206","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/hrt.2006.107524","article-title":"Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention.","volume":"93","author":"Bonello","year":"2007","journal-title":"Heart"},{"key":"R38-20250206","first-page":"473","article-title":"Evaluation of the myocardial protection of trimetazidine during percutaneous coronary intervention: a multi-center randomized and controlled clinical study.","volume":"49","author":"Chen","year":"2010","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"R39-20250206","first-page":"1399","article-title":"Clinical outcomes of trimetazidine in patients with acute ST segment elevation myocardial infarction without ST segment resolution after primary percutaneous coronary intervention.","volume":"89","author":"Peng","year":"2009","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"R40-20250206","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/000331979704800505","article-title":"Effects of trimetazidine on heart rate variability and left ventricular systolic performance in patients with coronary artery disease after percutaneous transluminal angioplasty.","volume":"48","author":"Birand","year":"1997","journal-title":"Angiology"},{"key":"R41-20250206","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1590\/S0066-782X2011005000079","article-title":"Trimetazidine on ischemic injury and reperfusion in coronary artery bypass grafting.","volume":"97","author":"Martins","year":"2011","journal-title":"Arq Bras Cardiol"},{"key":"R42-20250206","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2515\/therapie:2005061","article-title":"Trimetazidine induces Parkinsonism, gait disorders and tremor.","volume":"60","author":"Mart\u00ed Mass\u00f3","year":"2005","journal-title":"Therapie"},{"key":"R43-20250206","first-page":"4","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"24","author":"McDonagh","year":"2021","journal-title":"Eur J Heart Fail"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000862","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:18:44Z","timestamp":1786040324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":42,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000862","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}